Definitive Contract 75N91019C00016
Award Date
9/11/19
Potential Completion Date
12/15/20
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Pact & Health LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Branford, CT 06405, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a Definitive Contract to Pact & Health LLC, a for-profit limited liability company, for the I-PARTS INTEGRATED PLATFORM FOR ANTI-CANCER RADIATION THERAPEUTICS SCREENING project. The Firm Fixed Price contract, with a potential value of $298,822.00, was set aside for small businesses. The period of performance is from September 19, 2017, to June 18, 2018, and the place of performance...
The National Cancer Institute (NCI) awarded a $1,964,216.00 Firm Fixed Price contract to Pact & Health LLC, a small business, for the development of an "I-PARTS Integrated Platform for Anti-Cancer Radiation Therapeutics Screening" under TOPIC 366. The contract has a period of performance through June 15, 2022. This contract is a definitive contract and was set aside for small businesses. The I-PARTS platform aims to support the NCI's research efforts in developing new...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Woodtoga Holdings Company, a for-profit manufacturer, for the development of "Applicator-Compatible Electronic Brachytherapy Sources for Cancer Radiotherapy." The $399,779.00 firm fixed price contract runs through December 31, 2022 and is set aside for small businesses. This contract supports the SBIR...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Sibtech, Inc., a for-profit manufacturer, for the development of a positron emission tomography (PET) tracer to image the programmed death-ligand 1 (PD-L1) protein. The contract has a firm-fixed price of $349,735.00 and a completion date of April 17, 2021. The contract opportunity was initially posted on June 29, 2017, with...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a "Prostate Cancer Selective Radioactive Prodrug". This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>